Poseida Therapeutics, Inc.
DelistedCIK 1661460fmd_1GV4VEYB0AW0SEFQT7STR956V8Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2024, 23 periods
Latest annual · FY2023
Millions- Total revenues
- 65
- Operating income
- (130)
- Net income
- (123)
- Free cash flow
- (95)
Latest quarter · Q3 FY2024
Millions- Total revenues
- 72
- Operating income
- 20
- Net income
- 20
- Free cash flow
- (10)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
Poseida Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $64.7 million | $130.5 million | -50.4% | 10-K 2024-03-07 · proof |
| Operating income | -$129.5 million | -$59.9 million | 10-K 2024-03-07 · proof | |
| Net income | -$123.4 million | -$64 million | 10-K 2024-03-07 · proof | |
| Cash from operating activities | -$92.2 million | -$26.8 million | 10-K 2024-03-07 · proof | |
| Free cash flow | -$95.2 million | -$30.7 million | 10-K 2024-03-07 · proof | |
| Total assets | $273.9 million | $351.8 million | -22.2% | 10-K 2024-03-07 · proof |
| Total liabilities | $170.2 million | $164.2 million | +3.6% | 10-K 2024-03-07 · proof |
| Cash and cash equivalents | $44.5 million | $81.4 million | -45.4% | 10-K 2024-03-07 · proof |
- What was Poseida Therapeutics, Inc.'s revenue in fiscal 2023?
- Poseida Therapeutics, Inc. reported revenue of $64.7 million for fiscal 2023 (the year ended Dec 31, 2023), against $130.5 million the year before (-50.4%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Poseida Therapeutics, Inc.'s operating income in fiscal 2023?
- Poseida Therapeutics, Inc. reported operating income of -$129.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$59.9 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Poseida Therapeutics, Inc.'s net income in fiscal 2023?
- Poseida Therapeutics, Inc. reported net income of -$123.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$64 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Poseida Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Poseida Therapeutics, Inc. reported cash from operating activities of -$92.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$26.8 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Poseida Therapeutics, Inc.'s free cash flow in fiscal 2023?
- Poseida Therapeutics, Inc. reported free cash flow of -$95.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$30.7 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What are Poseida Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Poseida Therapeutics, Inc. reported total assets of $273.9 million, against $351.8 million a year earlier (-22.2%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What are Poseida Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Poseida Therapeutics, Inc. reported total liabilities of $170.2 million, against $164.2 million a year earlier (+3.6%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What are Poseida Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Poseida Therapeutics, Inc. reported cash and cash equivalents of $44.5 million, against $81.4 million a year earlier (-45.4%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1661460&period_type=annual&limit=5"Information only, not investment advice.